Additive inhibitory effects of treatment with an LHRH agonist and an antiandrogen on androgen-dependent tissues in the rat.
Combined treatment of adult male rats with the LHRH agonist, [D-Ser(TBU)6, des-Gly-NH2(10)]LHRH ethylamide, and a non-steroid antiandrogen, RU 23908, led to a rapid and marked atrophy of the ventral prostate and seminal vesicles. Treatment with the LHRH agonist decreased androgen secretion and thus facilitated the action of the antiandrogen in androgen-dependent tissues. Such a combined treatment could be useful in the treatment of androgen-dependent pathologies in man, particularly in prostatic adenocarcinoma and possibly benign prostatic hyperplasia.
D000818:Animals; D002064:Buserelin; D005640:Follicle Stimulating Hormone / Q000097:blood; D007987:Gonadotropin-Releasing Hormone / Q000031:analogs & derivatives* / Q000494:pharmacology; D007093:Imidazoles / Q000494:pharmacology*; D048289:Imidazolidines; D007986:Luteinizing Hormone / Q000097:blood; D008297:Male; D009929:Organ Size / Q000187:drug effects*; D011467:Prostate / Q000187:drug effects*; D051381:Rats; D011956:Receptors, Cell Surface / Q000187:drug effects; D011974:Receptors, LH; D012669:Seminal Vesicles / Q000187:drug effects*; D013739:Testosterone / Q000097:blood
D007093:Imidazoles; D048289:Imidazolidines; D011956:Receptors, Cell Surface; D011974:Receptors, LH; D007987:Gonadotropin-Releasing Hormone; D013739:Testosterone; C021277:nilutamide; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone; D002064:Buserelin